<DOC>
	<DOCNO>NCT00486135</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL147 subject solid tumor lymphoma . Both capsule tablet formulation evaluate . XL147 new chemical entity inhibit PI3 Kinase . Inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics XL147 ( SAR245408 ) Adults With Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . The subject histologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , know therapy prolong survival . An expanded cohort enrol ; NSCLC subject enrol must diagnosis relapsed refractory NSCLC ( Stage IIIB IV ) receive least two prior regimen include one platinumbased chemotherapy regimen . 2 . The subject histologically confirm diagnosis lymphoma relapse refractory standard therapy . 3 . For subject solid tumor , subject disease assessable tumor marker , physical , radiologic mean . There separate criterion apply subject lymphoma . 4 . Subjects indolent lymphoma must document disease status within 12 month prior study entry . 5 . The subject ≥18 year old . 6 . The subject 's weight ≥40 kg . 7 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . 8 . The subject adequate organ marrow function , fast plasma glucose ( FPG ) &lt; 160 mg/dL HbA1c &lt; 8 % screening . 9 . For subject solid tumor enrol expanded MTD cohort tumor genetic alteration subject : 1. tumor tissue amenable serial biopsy , 2. additional inform consent . 10 . The subject capable understanding comply protocol sign informed consent document . 11 . Sexually active subject ( male female ) must use medically acceptable method contraception course study 3 month follow discontinuation study drug . 12 . Female subject childbearing potential must negative serum pregnancy test screening . 13 . At least ten 410 micron tissue section , archival fresh , tissue block , subject 's tumor identify designated shipment sponsor allow local regulatory body . For subject lymphoma , tissue excisional core biopsy , case marrow involvement , bone marrow aspirate/biopsy acceptable . 1 . The subject previously treat selective PI3K inhibitor . 2 . Additional restriction prior treatment apply . 3 . For lymphoma subject : know central nervous system involvement , autoimmune disease require immunosuppressive therapy , systemic treatment prednisone &gt; 20mg/day equivalent within 2 week prior first dose XL147 , autologous stem cell transplantation within 12 week prior first dose , history allogeneic transplantation . 4 . The subject recover toxicity due prior therapy . 5 . The subject primary brain tumor . Subjects brain metastasis consider eligible subject receive radiation therapy brain metastasis within 2 week enrollment stable dose steroid 2 week . 6 . The subject currently receive anticoagulation therapeutic dos warfarin ( lowdose warfarin permit ) . 7 . The subject prothrombin time/partial thromboplastin time ( PT/PTT ) International Normalized Ratio ( INR ) test result screen 1.3x laboratory upper limit normal . 8 . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 9 . The subject psychiatric illness/social situation ( ) would limit compliance study requirement . 10 . The subject pregnant breastfeeding . 11 . The subject know positive human immunodeficiency virus ( HIV ) . 12 . The subject previously identify allergy hypersensitivity component XL147 formulation . 13 . The subject baseline correct QT interval ( QTc ) &gt; 460 ms. 14 . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>